Projected Income Statement: 9 Meters Biopharma, Inc.

Forecast Balance Sheet: 9 Meters Biopharma, Inc.

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 8.22 -0.53 -1.37 -37.6 -46.8 7.08
Change - -106.45% -358.49% -2,844.53% -224.47% -84.87%
Announcement Date 29/03/18 18/03/19 20/03/20 22/03/21 23/03/22 28/03/23
1USD in Million
Estimates

Cash Flow Forecast: 9 Meters Biopharma, Inc.

Fiscal Period: December 2017 2018 2019 2020 2021 2022
CAPEX 1 0.0387 0.0139 0.0119 0.002543 0.0125 0.002842
Change - -64% -14.41% -78.69% 390.6% -77.22%
Free Cash Flow (FCF) 1 -0.6136 -5.507 -5.448 -15.51 -19.91 -36.92
Change - 797.52% -1.08% 184.62% 28.38% 85.45%
Announcement Date 29/03/18 18/03/19 20/03/20 22/03/21 23/03/22 28/03/23
1USD in Million
Estimates

Forecast Financial Ratios: 9 Meters Biopharma, Inc.

Fiscal Period: December 2017 2018 2019 2020 2021 2022

Profitability

      
EBITDA Margin (%) - - - - - -
EBIT Margin (%) - - - - - -
EBT Margin (%) - - - - - -
Net margin (%) - - - - - -
FCF / Net Income (%) - - - - - -

Profitability

      
ROA -1,113.25% -311.44% -258.31% -58.07% -43.74% -63.03%
ROE 123.72% 305.2% 407.57% -545.95% -99.75% -198.92%

Financial Health

      
Leverage (Debt/EBITDA) -0.74x - - - - -0.17x
Debt / Free cash flow -13.39x - - - - -0.19x

Capital Intensity

      
CAPEX / Current Assets (%) - - - - - -
CAPEX / EBITDA (%) -0.35% -0.08% -0.05% -0.01% -0.04% -0.01%
CAPEX / FCF (%) -6.31% -0.25% -0.22% -0.02% -0.06% -0.01%

Items per share

      
Cash flow per share 1 0.0113 4.392 2.327 3.7 3.64 0.9701
Change - 38,865.86% -47.02% 58.99% -1.62% -73.35%
Dividend per Share 1 - - - - - -
Change - - - - - -
Book Value Per Share 1 -0.3859 -2.805 -4.871 3.142 3.222 0.1841
Change - 626.81% 73.64% -164.5% 2.57% -94.29%
EPS 1 -7.358 -19.52 -16.23 -11.64 -3.026 -3.378
Change - 165.22% -16.83% -28.27% -74.01% 11.65%
Nbr of stocks (in thousands) - 1,304 1,794 10,170 12,783 12,955
Announcement Date 29/03/18 18/03/19 20/03/20 22/03/21 23/03/22 28/03/23
1USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

  1. Stock Market
  2. Equities
  3. NMTRQ Stock
  4. Financials 9 Meters Biopharma, Inc.